Core Viewpoint - Recordati's subsidiary in China, Ruikangdi, has officially filed for deregistration, marking its complete exit from the Chinese market, which will result in the discontinuation of several rare disease medications, including the only oral drug for Cushing's syndrome, Osilodrostat [1][3]. Group 1: Company Actions - Ruikangdi's exit from the Chinese market will lead to the cessation of supply for its rare disease drugs, significantly impacting patients reliant on these medications [1]. - Osilodrostat was approved in China in September 2024 and commercialized in April 2025, but has been available since 2021 as part of a pilot program in Boao Lecheng [3]. Group 2: Patient Impact - The withdrawal of Ruikangdi is seen as a critical loss for Cushing's syndrome patients, as Osilodrostat is considered a "lifesaving drug" [3]. - A patient who has been on Osilodrostat for four years reported spending approximately 1 million yuan on the medication [3]. Group 3: Market Dynamics - Osilodrostat's price in China is around 8,000 yuan per box, with an average annual treatment cost of about 200,000 yuan, despite being one of the lowest-priced markets globally [3]. - The drug was expected to be included in the national medical insurance directory, which would have reduced out-of-pocket costs for patients to below 2,000 yuan per month, but it ultimately was not included [3]. Group 4: Industry Challenges - The high cost of developing rare disease drugs and the limited patient population make pricing and reimbursement a significant challenge, particularly in China where commercial insurance is still developing [4]. - The market for rare disease drugs is further complicated by the fact that only about 50 patients in China have purchased Osilodrostat, indicating low market penetration [4]. - The exit of Recordati is not an isolated incident, as other companies like BioMarin have also withdrawn rare disease treatments from the Chinese market, highlighting the difficulties faced by small to mid-sized firms in this sector [4][5].

Core Viewpoint - Recordati's subsidiary in China, Ruikangdi, has officially filed for deregistration, marking its complete exit from the Chinese market, which will result in the discontinuation of several rare disease medications, including the only oral drug for Cushing's syndrome, Osilodrostat [3][5]. Group 1: Company Actions - Ruikangdi's exit signifies a significant loss for Cushing's syndrome patients, as it is considered a "lifesaving drug" [5]. - Osilodrostat was approved in China in September 2024 and commercialized in April 2025, but has been available since 2021 as part of a pilot program [5]. - Recordati had high sales expectations for Osilodrostat in China, where it was priced at approximately 8,000 yuan per box, with annual treatment costs averaging around 200,000 yuan [5]. Group 2: Market Challenges - The drug's potential inclusion in the national medical insurance directory was anticipated, which could have reduced out-of-pocket costs for patients to below 2,000 yuan per month, but it ultimately was not included [5]. - The high cost of rare disease drug development and the limited patient population make pricing and reimbursement a significant challenge, especially in China where commercial insurance is still developing [6]. - Only about 50 patients in China are estimated to have purchased Osilodrostat, highlighting the drug's limited market penetration due to affordability issues [6]. Group 3: Industry Context - Recordati's exit is not an isolated incident; BioMarin also withdrew a rare disease treatment from the Chinese market in 2024, leaving patients without available options [7]. - The challenges faced by rare disease pharmaceutical companies include lengthy and costly market education and the financial burden on patients, many of whom struggle economically [7]. - Even drugs that are included in insurance plans can face supply issues, as seen with the drug Nitisinone, which experienced shortages despite being on the market for two years [7].

Group 1 - The high cost of developing rare disease drugs, combined with a limited patient base and high pricing, creates a challenging environment for small to medium-sized enterprises compared to larger pharmaceutical companies [1][4] - Recordati's Chinese subsidiary, Ruikangdi, has officially filed for deregistration, marking its complete exit from the Chinese market, which will result in the discontinuation of several rare disease drugs, including the only oral medication for Cushing's syndrome, Osilodrostat [1][3] - Osilodrostat was approved in China in September 2024 and commercialized in April 2025, but its sales have been limited, with only about 50 patients purchasing the drug in domestic pharmacies [3][4] Group 2 - The average annual treatment cost for Osilodrostat in China is approximately 200,000 yuan, despite the drug being priced at 8,000 yuan per box, which is among the lowest in the world [3][4] - The drug was expected to be included in the national medical insurance directory, which would have reduced out-of-pocket expenses for patients to below 2,000 yuan per month, but it ultimately did not make it into the final directory [3][4] - The exit of Recordati from the Chinese market is not an isolated incident, as other companies like BioMarin have also withdrawn their rare disease treatments, highlighting the ongoing challenges faced by rare disease drug manufacturers in China [4]

Core Viewpoint - The article highlights the critical shortage of the drug Nitisinone, used to treat Tyrosinemia Type I, in the Chinese market, affecting at least eight children who are facing a medication crisis due to the discontinuation of production by the overseas manufacturer [3][4]. Group 1: Drug Supply and Market Dynamics - Nitisinone was included in the first batch of encouraged generic drugs by the National Health Commission in 2019, yet no domestic generic versions have been launched to date [5]. - The shortage is attributed to the overseas manufacturer, which ceased production due to unmet sales expectations and raw material certification issues [9][10]. - The drug is the only effective treatment for Tyrosinemia Type I globally, and its absence illustrates the challenges in supplying rare disease medications, where small patient populations make it difficult for companies to justify production costs [5][9]. Group 2: Patient Impact and Treatment Options - Tyrosinemia Type I is a genetic metabolic disorder requiring lifelong treatment with Nitisinone to prevent toxic accumulation, which can lead to severe liver complications [7][8]. - The affected children are scattered across various provinces in China, with the youngest being only 3-4 months old [6]. - Alternatives such as liver transplantation are available but are typically reserved for cases where Nitisinone is ineffective, and some families are now forced to consider this option due to the drug shortage [7][16]. Group 3: Financial Implications for Families - The cost of Nitisinone is significant, with the price being approximately 4488 yuan per bottle, and families face steep out-of-pocket expenses if they resort to alternatives like overseas purchases [12][13]. - For instance, using Turkish generics could cost families around 96,000 yuan annually, while Swedish original drugs could reach up to 480,000 yuan per year [13]. - The current healthcare policies do not support reimbursement for drugs obtained through clinical emergency imports, further complicating the financial burden on families [15]. Group 4: Regulatory and Policy Challenges - The article discusses the potential for "clinical emergency product imports" as a short-term solution to the drug shortage, but this process is complex and may take considerable time to implement [14]. - The lack of local production and the small market size for rare disease drugs pose significant challenges for companies considering entering this space [14].

Core Viewpoint - The article highlights the critical shortage of the rare disease drug Nitisinone in China, affecting at least eight children, and emphasizes the challenges in the supply chain and market dynamics for rare disease medications [1][2]. Group 1: Drug Supply and Market Dynamics - Nitisinone has been included in the national medical insurance for two years but is currently facing a supply shortage due to the cessation of production by the overseas manufacturer [2][5]. - Despite being listed as the first drug in the "Encouraged Generic Drug List" by the National Health Commission in 2019, no domestic generic versions have been launched to date [2][6]. - The small patient population for rare diseases makes it difficult for companies to justify the production costs, leading to a lack of motivation for generic manufacturers to produce these drugs even after patent expiration [2][4]. Group 2: Patient Impact and Treatment Challenges - The affected children, with the youngest being only six months old, require lifelong treatment with Nitisinone to prevent toxic accumulation, which can lead to severe health issues [3][4]. - Families are facing a dilemma as the available stock from the distributor can only provide limited doses, and there are no plans for new supplies [3][5]. - Alternative treatment options, such as liver transplantation, are available but are primarily for patients who do not respond to Nitisinone, highlighting the urgency of the drug's availability [3][4]. Group 3: Financial Implications for Patients - The cost of Nitisinone is significant, with the price for the 5mg formulation being 4488 yuan, and patients face high out-of-pocket expenses even with insurance coverage [6][8]. - If families resort to purchasing the drug through international channels, the costs can escalate dramatically, making it unaffordable for many [7][8]. - The potential for "clinical urgent product import" exists, but it may not be a viable long-term solution due to regulatory and financial constraints [9][10].